New combo aims to fight merkel cell cancer when standard treatment fails
NCT ID NCT07472322
First seen Mar 27, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This study tests whether combining two drugs—ASTX727 (a pill) and retifanlimab (given through a vein)—can shrink tumors or stop them from growing in people with advanced Merkel cell cancer that no longer responds to standard immunotherapy. About 31 adults will take the drugs for up to 2 years, visiting the clinic every 2 weeks. The main goals are to see if the combination is safe and works better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Wisconsin-Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.